RPO NucleoGenesis

Private limited companyfounded 2022active for 4 yearsBassebeekstraat 39, 9031 Gent, BelgiumKBO/BCE: BE 0782.980.238

Summary

The computed 12-month bankruptcy probability of RPO NucleoGenesis is 3.8% (moderate). The 2023 annual accounts show equity of €20,385 and a net result of €2,885. Its solvency ranks better than 40% of 81 sector peers (NACE 21, financial year 2023). The company has been active since 2022 and the Belgian Official Gazette contains no insolvency or warning signals.

Risk analysisFollow Report Compare

RPO NucleoGenesisActive

Risk analysis Report Compare

Activity

Manufacture of basic pharmaceutical products and pharmaceutical preparations

NACE 21100

1 site

Size

€107,514total assets 2023

Equity: €20,385
Profit: €2,885

Turnover not published (micro format)

Financial health

Bankruptcy probabilitywithin 12 months: 3.8%

2023 figures too old to score

Structure

2023 accounts 16 days early1 of 4 deeds summarised

Signalsraises riskFigures for financial year 2023 (filed 15-07-2024)2 financial years not filed after the legal deadlineNo filing in 24 months (latest 15-07-2024)lowers riskLiquidity: current ratio 1.23, cash €96,962neutralLatest accounts filed on timeShow the evidence

Bankruptcy probability

No current score

Figures too old

The available figures for FY 2023 are too old to assess current financial health.

Financial strength, FY 2023

Average

Solvency 44

equity 19.0% of total assets

Liquidity 56

short-term debt 81.0% · cash 90.2%

Profitability 44

return on assets 2.7%

Bankruptcy probability, 12 months

3.8% Moderate

0%0.5%1.5%4%10%≥ 25%

About 4 in 100 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.3% (154 companies, NACE 21, micro)

Last 24 months 11-2024: 0.3% 12-2024: 0.3%● unchanged vs 11-2024 01-2025: 0.3%● unchanged vs 12-2024lowest value 02-2025: 0.3%● unchanged vs 01-2025lowest value 03-2025: 0.3%● unchanged vs 02-2025lowest value 04-2025: 0.3%● unchanged vs 03-2025 05-2025: 0.3%● unchanged vs 04-2025 06-2025: 0.3%● unchanged vs 05-2025 07-2025: 0.3%● unchanged vs 06-2025 08-2025: 0.5%▲ +0.2 percentage points vs 07-2025 09-2025: 0.6%▲ +0.1 percentage points vs 08-2025 10-2025: 1.2%▲ +0.6 percentage points vs 09-2025 11-2025: 1.0%▼ -0.2 percentage points vs 10-2025 12-2025: 1.2%▲ +0.2 percentage points vs 11-2025 01-2026: 1.8%▲ +0.6 percentage points vs 12-2025 02-2026: 1.8%● unchanged vs 01-2026 03-2026: 2.0%▲ +0.2 percentage points vs 02-2026 04-2026: 1.8%▼ -0.2 percentage points vs 03-2026 05-2026: 1.8%● unchanged vs 04-2026 06-2026: 1.8%● unchanged vs 05-2026 07-2026: 1.8%● unchanged vs 06-2026 08-2026: 3.8%▲ +2.0 percentage points vs 07-2026highest value 09-2026: 3.8%● unchanged vs 08-2026highest value 10-2026: 3.8%● unchanged vs 09-2026highest value

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Five signals.

lowers riskraises riskneutral

Figures for financial year 2023 (filed 15-07-2024)

NBB · annual accounts

2 financial years not filed after the legal deadline

NBB · filings

Liquidity: current ratio 1.23, cash €96,962

NBB · annual accounts

No filing in 24 months (latest 15-07-2024)

NBB · filings

Latest accounts filed on time

The financial year that closed on 31-12-2023 was due by 31-07-2024 and was filed on 15-07-2024, 16 days ahead of the deadline.

NBB · 1 filing

Deviation from the deadline

2023

16 days early

← before the deadline after the deadline →

tick = median of all Belgian filingsring = median in the sector

This company filed its 2023 accounts 16 days before the deadline; the sector median (NACE 21) for financial year 2023 is 13 days before the deadline, and 34% of those companies filed late.

Searched, nothing found (1)

No strike-offs in the KBO publications

Searched since incorporation in 2022.

KBO publications · our coverage

09-05-2025 Resignation: Richard Baum (bestuurder en voorzitter…Gazette deed
15-07-2024 Annual accounts filedfinancial year 2023 · micro…

Key points

Total assets 2023first financial year filed €107,514 View
Active since 2022founded 08-03-2022 4 years View

By topic

Financials

Financial year: 2023
Total assets: €107,514
Profit: €2,885
Solvency: 19.0%

Go to Financials

Timeline

Events: 2
Since: 2024

Go to Timeline

Company details

Sites: 1

Legal form: Private limited company
Activity: Manufacture of basic pharmaceutical products and pharmaceutical preparationsNACE 21100
Founded: 08-03-2022
Year ends: 31-12
Peppol: Reachable for e-invoices

Go to Company details

Key facts about RPO NucleoGenesis

What is the company number of RPO NucleoGenesis?: 0782.980.238. In Belgium the VAT number is the company number with BE in front: BE 0782.980.238.
Where is RPO NucleoGenesis based?: The registered office is at Bassebeekstraat 39, 9031 Gent.Company details
What does RPO NucleoGenesis do?: According to the KBO register, the main activity is manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21100).
What is the legal form of RPO NucleoGenesis?: Private limited company (BV).
When was RPO NucleoGenesis founded?: On 08-03-2022.
Is RPO NucleoGenesis still active?: Yes, RPO NucleoGenesis is an active enterprise in the KBO register.
What is the turnover of RPO NucleoGenesis?: Not stated in the processed annual accounts. The abridged format for small companies does not require turnover.Financials
Is RPO NucleoGenesis profitable?: In financial year 2023, RPO NucleoGenesis made a profit of €2,885.
Where can I find the annual accounts of RPO NucleoGenesis?: RPO NucleoGenesis filed 1 annual account with the National Bank of Belgium, for financial year 2023.